Systematic assessment with I-SCAN magnification endoscopy and acetic acid improves dysplasia detection in patients with Barrett's esophagus by Lipman, G et al.
 1 
Systematic assessment with i-scan magnification endoscopy 
and acetic acid improves dysplasia detection in patients with 
Barrett’s Esophagus 
G Lipman 1,2, R Bisschops 5, V Sehgal 1,2, JO Fernández-Sordo 3, R Sweis 2, JM 
Esteban 4, R Hamoudi 1,6, MR Banks 1,2, K Ragunath 3, LB Lovat 1,2, RJ Haidry 
1,2  
1Division of Surgery & Interventional Science, University College London; 2Department of Gastroenterology, University 
College Hospital NHS Foundation Trust, London; 3NIHR Nottingham Digestive Diseases Biomedical Research Unit, 
Nottingham University Hospitals NHS Trust, 4Hospital Clínico San Carlos, Madrid, Spain, 5Universitaire Ziekenhuizen 
Leuven, Belgium, 6Sharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, UAE. 
 
Word Count: 4036 (excluding abstract and references) 
Conflicts of interest: RJH has received research grant support from Pentax Medical, 
Cook Endoscopy and Covidien plc to support research infrastructure. KR has received 
research grant support from Pentax Medical 
All correspondence to: 
Dr Rehan Haidry, Consultant Gastroenterologist, Director of Endoscopy, 235 Euston Road, London, United 
Kingdom, NW1 2BU 
Email: r.haidry@ucl.ac.uk 
 
Acknowledgements; This work was undertaken at UCLH/UCL who received a proportion of funding 
from the UK Department of Health’s NIHR Biomedical Research Centers funding scheme.  The views 
expressed in this publication are those of the authors and not necessarily those of the Department of 
Health.  The work was also supported by the CRUK UCL Early Cancer Medicine Center. 
Abbreviations used in this paper: BE - Barrett’s esophagus; EAC - esophageal 
adenocarcinoma; ACA – acetic acid; HGD - high-grade dysplasia; LGD - low-grade 
dysplasia; IMC – intramucosal cancer; NBI - Narrow Band Imaging; PPV - positive 
predictive value; NPV - negative predictive value; PIVI - Preservation and 
Incorporation of Valuable endoscopic Innovations; ND-BE - non-dysplastic BE; D-
BE - dysplastic BE; IM – intestinal metaplasia. 
 
  
 2 
Abstract 
Background and Aims: 
Enhanced endoscopic imaging with chromoendoscopy may improve dysplasia 
recognition in patients undergoing assessment of Barrett’s Esophagus (BE). This 
may reduce the need for random biopsies detect more dysplasia. The aim of this 
study was to assess the effect of magnification endoscopy with i-Scan (Pentax, 
Tokyo, Japan) and acetic acid (ACA) on dysplasia detection in BE using a novel 
mucosal and vascular classification system. 
 
Methods:  
BE segments and suspicious lesions were recorded with high definition (HD) 
white light and magnification endoscopy enhanced using all i-Scan modes in 
combination. We created a novel mucosal and vascular classification system based 
on similar previously validated classifications for Narrow band Imaging (NBI). 27 
videos were rated before and after ACA application. Following validation, a further 
20 patients had their full endoscopies recorded and analysed to model use of the 
system in a routine clinical scenario to detect dysplasia. 
 
Results: 
The accuracy of the i-scan classification system for BE dysplasia improved with i-
scan magnification from 69% to 79% post-ACA (P= 0.012). Modeling a routine 
clinical scenario in 20 new patients, accuracy of dysplasia detection rose from 
76% using a ‘pull-through’ alone to 83% when ACA and magnification endoscopy 
were combined (P=0.047). Overall inter-observer agreement between experts for 
dysplasia detection was substantial (0.69). 
 
Conclusions: 
We have used a new i-scan classification system for BE and validated against 
similar systems with NBI with similar outcomes. When our classification is used 
in combination with magnification and ACA, it can detect BE dysplasia in clinical 
practice with a good accuracy. 
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Introduction 
Esophageal adenocarcinoma (EAC) is the 6th commonest cause of cancer related 
death in the United Kingdom [1] and the majority of cases are diagnosed at an 
advanced stage. The only known precursor is Barrett’s Esophagus (BE), which 
carries an estimated annual risk of progression to EAC of 0.3% [2]. Endoscopic 
surveillance to detect neoplasia at an early stage [3] permits successful minimally 
invasive endoscopic intervention [4–6]. 
The current gold standard for diagnosis remains histology. Guidelines recommend 
targeted biopsies of suspected areas followed by random sampling every 1-2cm 
throughout the BE segment (‘Seattle protocol’) [3][7]. Dysplasia can be focal and 
easily missed since less than 5% of the BE is actually sampled by the random 
biopsy technique [8]. Compliance with the Seattle protocol is poor and adherence 
worsens with longer BE segments [9]. A further drawback is the cost of analysing 
the large number of biopsies generated with a relatively low yield for dysplasia. 
 
To address these issues, enhanced endoscopic imaging seeks to identify dysplasia 
optically to allow targeted biopsy only. Enhanced imaging techniques include 
narrow band imaging (NBI) (Olympus Medical Systems, Tokyo, Japan), FICE 
(flexible spectral imaging color enhancement) (Fujinon In-telligent Chromo 
Endoscopy; Fujifilm, Tokyo, Japan), BLI (Blue Laser Imaging) (Lasereo; Fujifilm, 
Kanagwa, Japan), and i-Scan (Pentax, Tokyo, Japan). The most widely available is 
NBI. Several BE dysplasia classification systems have been suggested using NBI. 
All focus on ‘flat’ dysplasia, excluding nodular disease from analysis due to the 
presumption of dysplasia in these lesions. Between 2006 and 2008, 3 systems 
were proposed [10–12]. All describe changes in mucosal and vascular patterns 
following assessment of high quality still images. These basic principles of 
anomalies arising in vascular and mucosal micro structures in BE have formed the 
basis of all subsequent pieces of work creating and validating new classification 
systems with newer enhanced chromoendoscopy technologies. Several studies 
have validated these systems. Some focused specifically on the quality of the 
imaging rather than on the accuracy of detection of dysplasia [13–15]. One study 
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addressed classification systems using videos [16] but separated sensitivity and 
specificity for dysplastic and non-dysplastic lesions, so overall parameters are 
hard to determine. Nevertheless, sensitivity varied from 0.31-0.64 for non-
dysplastic lesions amongst experts with a specificity of 0.50 – 0.76. For dysplastic 
lesions, these rose to 0.62-0.83 and 0.64-0.88 respectively. In a well-designed 
international randomised controlled trial of NBI compared to routine endoscopy, 
NBI detected dysplasia with an accuracy of 81% [17]. This work was similar to 
work presented by our group in 2014 using i-Scan [18]. 
 
Recently, a consortium of NBI experts, the BING consortium, developed a 
simplified consensus driven NBI classification system of BE following a review of 
60 NBI magnification images. The mucosa was classified as normal (circular, 
ridged or tubular pattern) or abnormal (absent or irregular patterns) and the 
vasculature was either normal (regular vessels with normal or long branching 
patterns) or abnormal (focally or diffusely distributed vessels following abnormal 
mucosal architecture). Lesions with abnormal mucosal pattern or vasculature 
pattern or both were classified as dysplastic. This reported an overall accuracy of 
0.85, sensitivity 0.80%, specificity 0.88, positive predictive value (PPV) 0.81 and a 
negative predictive value (NPV) 0.88, with substantial overall inter-observer 
agreement (κ =0.68). These high quality data have set a benchmark for other 
technologies to try and match or improve.  
 
Some previous studies have used ACE in combination with virtual 
chromoendoscopy to generate classifications in BE. Chromoendoscopy with ACA 
results in an aceto-whitening reaction, highlighting the mucosal pattern and can 
potentially show the underlying vasculature in areas that have lost aceto-
whitening. Dysplastic lesions lose aceto-whitening and appear red compared with 
non-dysplastic areas, permitting targeted assessment and sampling. A recent 
meta-analysis of 9 studies, calculated a pooled sensitivity of 92% and specificity 
of 96% for the diagnosis of high grade dysplasia or intramucosal cancer [19]. 
 
In light of emerging new technologies and the need to reduce unnecessary burden 
and cost on histopathology services, the Preservation and Incorporation of 
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Valuable Endoscopic Innovations (PIVI) initiative of the American Society for 
Gastrointestinal Endoscopy (ASGE) has set thresholds that any new technology 
should meet for dysplasia detection in BE before the existing practice of random 
biopsies can be replaced [20]. These thresholds have been set at a per patient 
sensitivity ≥90%, per patient NPV ≥98% and a specificity ≥80% [20]. 
 
A novel virtual chromoendoscopy technology, i-Scan (Pentax Hoya, Japan), utilises 
post-processing technology to provide surface and contrast enhancement in 3 
modes (surface enhancement - mode 1, contrast enhancement - mode 2, combined 
surface and contrast enhancement - mode 3). A new Pentax EG-2990Zi MagniView 
endoscope permits magnification endoscopy of up to 136 times of the mucosa in 
all i-Scan modes to further characterise the mucosa and micro-vasculature in great 
detail. 
 
Aims 
 
The aims of this study were: 
 To validate a previously reported Narrow Band Imaging (NBI) 
classification system using mucosal and vascular structures with i-Scan 
magnification endoscopy and acetic acid chromoendoscopy. 
 To evaluate whether a systematic assessment using ACA and magnification 
endoscopy improves the accuracy of dysplasia detection with this 
validated classification system in a routine clinical scenario. 
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Methods 
Patients: 
Patients were invited to enrol if they were undergoing surveillance of BE or 
endoscopic assessment prior to treatment of dysplasia between January 2013 and 
January 2015. The study had ethical approval and was registered with ISRCTN 
(Registration: 58235785). Exclusion criteria included pregnancy, symptomatic 
esophageal strictures, erosive esophagitis, varices and prior treatment to the 
esophagus, including endoscopic mucosal resection, radiofrequency ablation or 
radiotherapy.  
 
Following informed consent, patients underwent routine upper GI endoscopy 
with a high definition magnification endoscope (Pentax EG-2990Zi MagniView 
endoscope, i-Scan EPK-i7000 High-Definition Video Processor) with a distal cap 
attachment. This allowed the endoscopists to isolate areas of interest for 
magnification. 
 
A detailed examination of the BE segment was performed using high definition 
white light endoscopy (HD-WLE) followed by all i-Scan modes. The esophageal 
mucosa was washed with Simethicone and 2% N-Acetyl cysteine via a spray 
catheter. Excess gastric secretions and fluid were aspirated from the stomach. 
Initial examination was performed using HD-WLE, from the top of the gastric folds 
to the squamo-columnar junction and the entire esophagus was imaged from the 
centre of the lumen, this was repeated in i-Scan modes 1,2 and 3 (surface 
enhancement, contrast enhancement and tone enhancement). Each i-scan mode 
delivers unique information about a lesion and therefore when used in 
combination can provide an overall assessment of a potentially abnormal area. 
Nodules ≥10 mm or ulcers were excluded, in keeping with similar studies [21]. 
Areas of suspected dysplasia were then recorded with magnification endoscopy 
in white light and in all i-Scan modes. After all areas of interest had been examined, 
2% ACA was administered and the process repeated. A corresponding biopsy or 
mucosal resection specimen was taken to confirm pathology from areas of interest 
and further random biopsies consistent with the Seattle Protocol were taken 
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throughout the BE segment. Two expert gastrointestinal histopathologists 
reviewed all pathological samples.  
 
Utilization of i-scan modes and ACA 
 
i-Scan (Pentax Hoya, Japan), utilises post-processing technology to provide  
enhancement in 3 modes. The endoscopist can switch between modes in real-time 
whilst assessing the BE segment with a push of a button on the scope. i-Scan 1, 
surface enhancement, utilises the technology to detect the edge of a lesion by 
comparing the difference in pixels and then digitally enhancing the difference 
resulting in sharper contrast between structures. i-Scan 2, contrast enhancement, 
detects darker areas of the image and includes blue colour before an algorithm 
enhances the image resulting in a blueish-white staining of depressed areas and 
vasculature. i-Scan 3, tone enhancement, dissects and reconstructs the red, green 
and blue component of each image to provide enhancement of the mucosal 
structures, vascular patterns and changes in colour. i-Scan 1 is often the default 
setting in clinical practice for lesion detection. i-Scan 2 allows for assessment of 
mucosal and vascular structures in lesion characterization and i-Scan 3 enhances 
glandular structures and is used for lesion demarcation. 
 
In our study, all modes were used in an inter-changeable manner for each video 
and experts were able to view all lesions allowing them to use the particular 
enhancement that best suited the lesion in question. Some lesions were only 
identified with mucosal abnormalities and therefore i-Scan 1 was preferred, 
whereas others had more pronounced vascular abnormalities and therefore i-scan 
2 or 3 were better. ACA is excellent at highlighting the mucosa though mucosal 
hyperemia and for identification of abnormal areas with loss of aceto-whitening. 
However, once an area has lost aceto-whitening, the vasculature remains visible 
and using i-Scan modes 2 and 3 can easily be assessed (as per the examples seen 
below in Figures 1 and 2) 
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Validation of the NBI Classification System Using i-Scan 
Patients undergoing endoscopy at 3 tertiary referral centres (UCLH, Nottingham 
University Hospital and Universitaire Ziekenhuizen Leuven) were included. 
Videos were collected targeting individual areas both before and after ACA 
administration. Videos were converted to MP4 format using Brorsoft Video 
Converter and edited on an Apple Mac using iMovie software. Clips were exported 
as 1080p HD videos.  A corresponding biopsy or endoscopic resection specimen 
was taken from all recorded areas to confirm the histological diagnosis.  
 
Two independent expert GI pathologists reported all biopsies.  The consensus 
report was considered the gold standard. Specimens were graded as NDBE, 
indefinite for dysplasia (IND), low-grade dysplasia (LGD), or HGD/EAC. Only 
specimens that confirmed NDBE, HGD or EAC were used to develop the 
classification system.  
 
A single editor edited all videos. The six experts viewed videos on a HD screen in 
a randomly assigned order to ensure they were blinded to both diagnosis and 
pairing of lesions (before and after ACA).  Sensitivity, specificity, PPV and NPV was 
calculated for detection of dysplasia both before and after administration of ACA.  
Modeling of Clinical Scenario 
 
Further videos from 20 patients were collected from the three sites. This time, 
videos were created from the entire endoscopy rather than from assessments only 
of individual lesions. Each patient had at least one area identified for targeted 
magnification endoscopy with a biopsy or mucosal resection. For each patient 4 
video clips were viewed in a blinded fashion, a ‘pull-through’ assessment of the 
entire BE segment before ACA, a second ‘pull-through’ after ACA, the lesion before 
ACA and the lesion after ACA. All experts met in February 2016 and individually 
viewed the lesion videos on HD iPads at the same time in a random order. After 
this, the pull-through videos were also displayed in random order.  
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Lesions suspicious for dysplasia on ‘pull-through’ were recorded by experts with 
a time (seconds into the clip) and location on a clock face (anterior wall lesion = 
12 o’clock, right wall = 3 o’clock etc). If no dysplasia was seen, the ‘pull-through’ 
was reported as normal. 
 
A clinical scenario was then modeled to represent real time endoscopic 
assessment. Videos were interpreted as in clinical practice with 4 steps; step 1, a 
‘pull-through’ with i-Scan assessment before application of ACA, step 2, focus on 
any abnormal areas, step 3, a repeat pull-through after application of ACA and step 
4, a further assessment of any previously noted areas of interest and any new 
areas seen after ACA. On a per patient basis the sensitivity, specificity, PPV and 
NPV was calculated at each of these steps to determine the change in yield when 
ACA was combined with magnification endoscopy and i-Scan enhancement. If no 
abnormality was detected at step 1 then no detailed assessment of a lesion would 
occur and the result of step 2 would be ignored. If, however, a lesion was identified 
at step 1 then all further detailed assessments would be included.  Similarly, if a 
suspicious lesion was noted at any subsequent step, then all further steps would 
be assessed by the clinician. The process is summarised in figure 3. 
 
 
 
Statistical Analysis 
 
There are no prior studies of i-Scan to detect dysplasia in BE. However, earlier 
work by our group using i-Scan without ACA reported dysplasia was detected with 
an accuracy of 69% (Standard deviation 4%), sensitivity of 67% (Standard 
deviation 26%) and specificity of 69% (Standard deviation 15%) [18]. 
 
The BING group aimed for a 4% improvement in the accuracy of diagnosing 
dysplasia using the NBI classification system with a power of 80% and assumed a 
one sided α of 0.05. Using earlier work from our group, the mean accuracy of the 
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i-Scan Classification System was 75% with a SD 0.14. A power calculation was 
performed to calculate the number of videos required to demonstrate a 4% 
improvement in the accuracy of diagnosing dysplasia with a power of 90%. An 
improvement of 4% was chosen to mirror the improvement level set by the BING 
group who also assumed a one-sided significance level of 0.05 [21].  A one-sample 
t test power calculation was performed using R/Bioconductor version 3.2.5 using 
the power.t.test function [22]. Twenty-seven videos with 6 scorers would be 
required to determine if the mean accuracy could be improved by 4%, using ACA 
in the i-Scan Classification System. 
 
Sensitivity, specificity, accuracy, PPV and NPV were calculated using the inter-
observer data. Paired t-test was used to determine significant difference between 
the groups. Statistical significance cut-off was taken as p < 0.05. Inter-observer 
agreement was calculated using k-statistics and a modified Likert scale developed 
by Landis and Koch [23] was used to interpret k values (poor <0.20; fair =0.21-
0.40, moderate =0.41-0.60, substantial =0.61-0.80; very good =0.81-1.00). IBM 
SPSS was used for analyses. Cohen's kappa test and 95% C.I were calculated using 
the Kappa.test function in the FSMB library in R/Bioconductor version 3.3.3. 
 
 
Results 
The expert-group developed a consensus scoring system based on mucosal (M) 
and vascular (V) patterns: M1 regular oval or villous pits and M2 irregular or 
featureless mucosa; V1 regular vessels and V2 irregular (dilated or corkscrew) 
vessels (Table 1; Figures 1 and 2). Predicted dysplasia was calculated based on 
mucosal and vascular pattern scores (Table 2). This was very similar to all 
previous classification systems used in BE with NBI [10–12,21].   
 
An area was classified as non-dysplastic only when both normal mucosal and 
vascular patterns were present (M1V1) (Table 2).  
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Validation of NBI Classification System Using i-Scan 
 
For validating our i-scan classification against the previous NBI system, 27 lesions 
were recorded in 21 new patients undergoing assessment for BE dysplasia. Mean 
age was 69 (range 33-84), 82% were male. Using Prague criteria, mean 
circumferential extent of BE was 3 cm (range 0-12 cm) and the mean maximal 
extent was 5 cm (range 1-15 cm) (Table 3).  Experts rated each video using the 
classification system defined in phase 1.  
 
Mean video length was 28 seconds for both non-dysplastic BE (ND-BE) and 
dysplastic BE (D-BE) lesions. The length of videos before and after ACA was not 
statistically different (29 seconds vs. 27 seconds, p=0.25). 
 
Of the 324 video evaluations (54 by each of 6 experts), classification was uncertain 
in only 4.6%. Reasons included lack of focus and uninterpretable mucosal or 
vascular pattern. Pathology was predicted as ND-BE or D-BE based on the experts’ 
classification of mucosal and vascular patterns.  
 
ACA improved the experts’ mean overall accuracy from 69% to 79% (p=0.01) for 
dysplasia detection. There was a trend following ACA of improved sensitivity 
(79% vs. 87%, p=0.08) and specificity (53% vs. 68%, p=0.07) of the classification 
system though neither reached statistical significance. Inter-observer agreement 
was fair (κ = 0.261) pre ACA and moderate (κ = 0.403) after ACA, 95% C.I 0.03 to 
0.83 (Table 4).  
 
Only 2 lesions with LGD were included in the validation phase of the study. All 6 
experts scored one lesion abnormal and 5 of the 6 experts scored the second lesion 
abnormal, the remaining expert felt unable to interpret the clip. 
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Modeling of Clinical Scenario 
 
In the modeling of a clinical scenario, the same experts from the working group 
reviewed 79 videos (40 clips of pull-throughs and 39 videos of lesions) from 20 
patients not previously seen.  Experts’ diagnosis of ND-BE or D-BE was recorded 
for each pull-through video and magnification video. Median video length was 
similar for non-dysplastic and dysplastic pull-throughs (72 seconds vs. 66 
seconds, non-paired T-test p=0.26) and for non-dysplastic and dysplastic lesions 
(31 seconds vs. 32 seconds, non-paired T-test p=0.65). 
 
 
No uncertainty was reported in any of the 240 pull-through video evaluations (40 
by each of 6 experts). Of the 234 lesion assessments (39 by each of 6 experts), 
8.1% were felt to have an uncertain classification. Pathology was again predicted 
based on classification of mucosal and vascular patterns (Table 2). If a lesion was 
not classified, the result of the previous step was recorded.  
 
Interpreting the clips as a clinical scenario, the addition of magnification 
endoscopy (Step 1 versus Step 2) or ACA (Step 1 versus Step 3 or Step 2 versus 
Step 4) alone did not significantly improve accuracy or sensitivity. However, the 
complete protocol of magnification endoscopy with the classification system 
followed by ACA did significantly improve the accuracy. Inter-observer agreement 
at step 4 of the process was substantial (κ =0.69), 95% CI: 0.36 to 1.01 (Table 5).  
 
Sub-group analysis comparing LGD (n=3) and non-dysplastic lesions (n=8) 
demonstrated similar results. The addition of magnification endoscopy and ACA 
significantly improved the accuracy and specificity of dysplasia detection and 
diagnosis (Table 6). 
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Discussion 
Early identification of dysplasia through endoscopic surveillance of BE allows 
patients access to minimally-invasive endoscopic eradication therapy. There is 
however limited data to show that surveillance in patients with BE impacts 
significantly on overall survival. The ProBar group examined 783 patients in a 
multicentre prospective study to examine the clinical benefit of BE surveillance 
[24]. They concluded EAC was diagnosed at an earlier stage during BE surveillance 
than in the general population (p<0.001) and carried a similarly good prognosis 
to non-surveillance patients diagnosed at the same stage of disease.  These 
findings strengthen the case for routine endoscopic surveillance of BE.  
 
With the on-going advancements in endoscopic imaging it is vital to utilise these 
tools in a structured manner to give the endoscopist every chance to diagnose 
dysplasia accurately. i-Scan post-processing endoscopic imaging has been shown 
superior to white light in the detection of IM in BE in previous studies [20]. In our 
study we used a combination of i-Scan enhancements coupled with magnification 
endoscopy and ACA to allow experts to identify Barrett’s associated dysplasia 
through early changes in mucosal and vascular patterns using a simple 
classification system that has previously been validated using NBI [21]. Following 
a systematic assessment of Barrett’s Esophagus using ACA and magnification 
results in an accuracy of 83%, with substantial inter-observer agreement (κ 
=0.69). These are on par with previous data for similar classification systems. 
 
Several NBI endoscopic classification systems that were developed to identify 
dysplasia have focused on the mucosal and vascular patterns [10–12]. Evaluation 
and validation of these systems has relied on the use of selected still images 
[14,25]. Two studies have, however, used videos to validate these classification 
systems, Baldaque-Silva et al evaluated NBI with optical magnification videos by 
6 endoscopists with varying degrees of experience [26]. Dysplasia detection 
varied from 62-90% with inter-observer agreement (κ) ranging 0.39-0.48. A 
further study using videos compared classification systems and reported accuracy 
of ‘experts’ for diagnosing dysplasia was 0.75-0.78 with no significant difference 
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across the scoring systems. However, global κ agreement scores were moderate 
for the Kansas (0.44) and Amsterdam (0.47) systems and only fair for the 
Nottingham (0.34) classification system [27].  
 
Recently, a consortium of NBI experts, the BING consortium, developed a 
simplified consensus driven NBI classification system of BE following a review of 
60 NBI magnification images. This was validated with still images and following a 
web-based survey reported overall accuracy 0.85, sensitivity 0.80%, specificity 
0.88, positive predictive value (PPV) 0.81 and a negative predictive value (NPV) 
0.88, with substantial overall inter-observer agreement (κ =0.68). Of note, 
analysis was performed on a per-image rather than per-patient basis [21].   
 
Ours is the first clinical study with endoscopic videos to validate this classification 
system using i-Scan technology and demonstrate a benefit in clinical practice 
through an improvised real time clinical scenario. The scenario was designed to 
reflect real-life endoscopic assessment of BE; a general view of the BE segment 
before focusing on areas of suspicion and repeating the process after application 
of ACA. Magnification endoscopy with i-Scan can identify the same mucosal and 
vascular features described with NBI. Our study validates the use of the NBI 
classification system with i-Scan technology using an international group of expert 
endoscopists viewing videos collected from several European centres. Addition of 
ACA significantly raised the accuracy of the classification system using i-Scan from 
69% to 79% (p=0.012). Further, in our model of routine clinical practice, accuracy 
of dysplasia detection was significantly improved with magnification endoscopy 
and ACA compared to HD-WLE and i-Scan alone (83% vs. 76%, p=0.047). Inter-
observer agreement of the classification system is moderate but when 
incorporated into a clinical decision making protocol, it improves to substantial (κ 
= 0.69). This later scenario mimics what happens in daily clinical practice and is 
therefore likely to be a reasonably accurate representation of real life endoscopy. 
Sub-group analysis of LGD lesions alone generates similar results, with an 
accuracy of 80% although these number are very small. 
 
 
 15 
The results of this study do not meet the current PIVI thresholds for adopting i-
Scan magnification endoscopy with ACA instead of the current practice of random 
biopsies. However, this may reflect the low number of lesions reviewed, the 
prevalence of dysplasia in our sample population and the use of videos rather than 
still images.  
 
Following an improvised clinical scenario to replicate the real life diagnostic 
endoscopic approach and analysis on a per-patient basis, i-Scan magnification 
with ACA has a higher sensitivity than the BING study (85% vs. 80%) but a lower 
specificity (80% vs. 88%) and accuracy (83% vs. 85%), though has similar inter-
observer agreement (0.69 vs. 0.68) [21]. Direct comparisons are, however, 
difficult as the BING study and most others of NBI were based on assessment of 
still images. It is reasonable to assume that the images chosen for analysis in all 
these studies would have been the best images available.  A limitation of the 
current study like those using still images is the bias introduced by cherry picking 
optimal views, which may not be achievable in clinical practice. Imaging studies 
rarely reflect true clinical experience and although this study design has tried to 
imitate a protocol that can be followed in clinical practice, ultimately, endoscopists 
can choose to focus on areas of suspicion that may be visible after more than a 
minute of observation. Nevertheless, this study, based on assessment of videos, is 
likely to closer represent the real clinical scenario.  
 
It should also be noted that the pull-through videos after ACA were significantly 
shorter than pre-ACA videos, although this may represent real life clinical practice 
that less time is spent looking following an initial evaluation. 
 
Previous studies have identified nodules and ulcers in BE as high risk for dysplasia 
and neoplasia [28]. This and similar studies excluded lesions >10 mm. However, 
advances in endoscopic technologies with optical magnification makes previously 
unrecognised small nodules and ulcers visible, which may bias experts to classify 
these lesions as dysplastic. The field continues to develop with increasingly good 
imaging techniques. We suggest that future studies should include assessment of 
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small nodules and superficial ulcers to determine whether they improve dysplasia 
classification.  
 
 
Future work using the i-Scan and NBI classification systems should assess both 
still images and videos from the same cohort to quantify whether images are a 
valid reference tool, as most endoscopists rely on video footage rather than stills 
for diagnostic purposes. A larger study using i-Scan technology may enable PIVI 
thresholds to be met, particularly if micro-nodularity and superficial ulceration 
are included in the assessment. A further project comparing NBI with i-Scan 
technology may be able to provide a classification system that is validated across 
all technologies. 
 
In summary, we present data validating the NBI classification system using i-Scan 
endoscopy with magnification endoscopy and ACA. This system has good 
sensitivity and specificity with fair inter-observer agreement using i-Scan. 
Combining i-Scan magnification endoscopy with ACA can be used in a step-wise 
manner resulting in high accuracy, sensitivity and specificity with substantial 
inter-observer agreement. The proposed protocol may reduce the need for 
random biopsies for dysplasia detection. 
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Figure 1: SHOWING EXAMPLES OF VARIOUS I-SCAN MODES WITH 
MAGNIFICATION DEMONSTRAING THE NORMAL (V1) AND ABNORMAL (V2) 
MICRO-VASCULATURE WITH AND WITHOUT THE ADDITION OF ACETIC ACID. 
 
a) Examples of normal micro-vasculature (V1) as seen with various i-scan 
modes without acetic acid (regular and uniform microvasculature – 
shown by arrows) 
b) Examples of normal micro-vasculature (V1) as seen with various i-scan 
modes after the addition of acetic acid (regular and uniform 
microvasculature – shown by arrows). Despite the hyperaemia caused by 
the addition of ACA one can still make out the underlying regular vessels. 
c) Examples of abnormal micro-vasculature (V2) as seen with various i-scan 
modes without acetic acid (irregular, distorted and tortious 
microvasculature – shown by arrows) 
d) Examples of abnormal micro-vasculature (V1) as seen with various i-scan 
modes after the addition of acetic acid (irregular, distorted, dilated and 
tortious microvasculature – shown by arrows). Despite the hyperaemia 
caused by the addition of ACA one can still make out the underlying 
irregular vessels. 
 
 
Figure 2: SHOWING EXAMPLES OF VARIOUS i-SCAN MODES WITH 
MAGNIFICATION DEMONSTRATING THE NORMAL (M1) AND ABNORMAL (M2) 
MICRO-MUCOSA WITH AND WITHOUT THE ADDITION OF ACETIC ACID. 
a) Examples of normal micro-mucosa (M1) as seen with various i-scan 
modes without acetic acid (regular and uniform mucosal patterns – 
shown by arrows) 
b) Examples of abnormal micro-mucosa (M2) as seen with various i-scan 
modes without acetic acid (irregular, featureless and distorted mucosal 
patterns – shown by arrows) 
c) Examples of normal micro-mucosa (M1) as seen with various i-scan 
modes with acetic acid (regular and uniform mucosal patterns – shown by 
arrows) 
d) Examples of abnormal micro-mucosa (M2) as seen with various i-scan 
modes with acetic acid (irregular, distorted and featureless mucosal 
patterns – shown by arrows) 
 
Figure 3: Modelling of interpretation of dysplasia detection in 4 stages of 
endoscopic examination to replicate real time clinical decision-making. 
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Table 1: i-Scan Magnification Classification System for the detection of dysplasia 
in BE 
Mucosal Pattern M1 Regular circular or villous pits  
 
M2 Distorted or irregular pits  OR Featureless 
mucosa  
Vascular Pattern V1 Regular and uniform vessels 
 
V2 Irregular, dilated corkscrew vessels 
 
 
 
Table 2: Interpretation of M and V scores 
MV classification Diagnosis 
M1 V1 NO DYSPLASIA 
M1 V2 DYSPLASIA 
M2 V1 DYSPLASIA 
M2 V2 DYSPLASIA 
 
 
 
Table 3: Patient Characteristics for the Validation of the NBI Classification System 
Using i-Scan 
Number of Patients 21 
Number of lesions recorded 27 
Mean Age (range) 69 (46-83) 
Male 86% 
Mean Barrett’s Circumferential Length (cm, 
range) 
3 (0-12) 
Mean Barrett’s Maximal Length (cm, range) 5 (1-15) 
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Table 4: Validation of the i-Scan Classification System for BE 
 Mean Pre ACA Mean Post ACA Paired t-test p value 
Accuracy 69% (SD 13%) 79% (SD 11%) 0.012 
Sensitivity 79% (SD 10%) 87 %(SD 14%) 0.081 
Specificity 53% (SD 23%) 68% (SD 21%) 0.067 
PPV 73% (SD 11%) 81% (SD 13%) 0.112 
NPV 63% (SD 16%) 81% (SD 17%) 0.016 
Cohen’s κ 0.261 0.403  
95% C.I -0.18 to 0.68 0.03 to 0.83  
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Table 5: Results for each step of the protocol as per the clinical modelling scenario 
(Step 1, a pull-through, Step 2, a focus on any abnormal area, Step 3, a pull-through 
after application of ACA and Step 4, a further assessment of any previously noted 
areas of interest and any new areas seen after ACA) in all patients.  
 
Step 1 Step 2 Step 3 Step 4 
Paired t-test 
P value 
Step 1 vs. Step 4 
Accuracy 76% 77% 75% 83% 0.047 
Sensitivity 91% 81% 94% 85% 0.19 
Specificity 57% 74% 52% 80% 0.0008 
PPV 72% 77% 70% 84% 0.005 
NPV 84% 78% 88% 81% 0.63 
Cohen’s κ 0.667 0.365 0.679 0.690  
95% C.I. 0.22-1.09 0.18-1.0 0.28-1.09 0.36-1.01  
 
Table 6: Results for each step of the protocol as per the clinical modelling scenario 
(Step 1, a pull-through, Step 2, a focus on any abnormal area, Step 3, a pull-through 
after application of ACA and Step 4, a further assessment of any previously noted 
areas of interest and any new areas seen after ACA) in all patients with LGD alone. 
 
 
Step 1 Step 2 Step 3 Step 4 
Paired t-test P 
value 
 Step 1 vs. Step 4 
Accuracy 64% 68% 63% 80% <0.001 
Sensitivity 78% 57% 94% 88% 0.17 
Specificity 59% 71% 52% 78% 0.003 
PPV 39% 36% 40% 56% 0.04 
NPV 89% 85% 97% 95% 0.12 
Cohen’s κ 0.657 0.25 0.625 0.621  
95% CI 0.22 - 1.09 -0.35 - 0.85 0.15 - 1.09  0.22 - 1.09  
 
